Lexaria Bioscience Corp.
LEXXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLexaria Bioscience Corp. operates as a biotechnology company. With a market capitalization of $6.5M, it sits in micro-cap territory. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
Market Cap
$6.5M
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
-7.90
EPS (TTM)
$-5.25
EPS (Fwd)
$-0.39
ROE
-162.8%
ROA
-81.3%
Cash
$3.6M
Total Debt
$86,714
Free CF
-$4.7M
52W Change
-77.9%
Annual Financials
Cash vs Debt
Where LEXX stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, LEXX finished 65.09% below its 150-day moving average ($9.28) and 66.14% below its 200-day moving average ($9.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LEXX overbought or oversold?
At the October 7, 2026 close, LEXX's RSI(14) was 53.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.6M in cash and $87K in debt, LEXX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$4.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -162.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $255K (2022) to $706K (2025), reflecting a 176% increase over the period.
LEXX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Lexaria Bioscience Corp.'s trajectory.